Healthcare Professionals

Avalus™ Bioprosthesis

Pericardial Aortic Surgical Valve

ADVANCED AND EFFICIENT

Avalus™ Bioprosthesis is the Next Generation stented pericardial aortic valve, developed by Medtronic to advance cardiac surgical care. A powerful synergy of experience and innovations for better performance, improved implant experience and life-time patient management. 

STRONG CLINICAL PERFORMANCE

With Avalus™ Bioprosthesis your patients will benefit from efficient and stable hemodynamics, proven by high-quality clinical evidence1.​

GOOD SAFETY PROFILE 100% FREEDOM FROM SVD THROUGH 4 YEARS

 

>94% OF PATIENTS OVER 4-5 YEARS 
WITH LESS THAN MILD CENTRAL 
REGURGITATION1

>72% OF PATIENTS CONTINUE REPORTED NYHA CLASS I AT 4&5 YEARS

 

The PERIGON Pivotal trial confirmed substantial improvements of peak and mean aortic pressure gradients and mean EOA after implantation of the Avalus™ Bioprosthesis, and these improvements were maintained over time1.

Mean Gradients and Effective Orifice Area

Echocardiographic Findings

The PERIGON Pivotal trial demonstrated no trace or extremely low cases of severe transvalvular regurgitation after Avalus™ Bioprosthesis implantation1

Transvalvular Regurgitation ​

Transvalvular Regurgitation

IMPLANTERS EXPERIENCE ​

Sizing and surgical technique are critical to hemodynamic and durability outcomes in patients receiving surgical aortic valve treatment. Watch the video with Prof. Michael G. Moront and learn about his experience in implanting Avalus™ Bioprosthesis.

Product Details

A design platform for long-term durability

  • AOA™ tissue treatment to mitigate calcification*
  • Interior-mounted leaflets minimize damaging  contact with the frame

Avalus features

IMPROVED IMPLANT EXPERIENCE

Avalus
  • Soft and pliable sewing cuff facilitates needle penetration, suture placement, and valve seating for an improved implant experience
  • Lower valve profile and narrow commissure posts expands ostia clearance and gives you more space for knot tying
  • Streamlined valve holder improves visibility in both standard and minimally invasive approaches
  • Simple one-cut release

PERFORMANCE AND LIFETIME MANAGEMENT

Avalus
  • Designed to achieve 100% coaptation and minimize central regurgitation
  • Valve dimensions and geometry enable future ViV replacements
  • PEEK base frame impregnated with Barium Sulfate provides for radiopacity and visibility
  • Polymer frame mitigates the risk of potential metal on metal corrosion with transcatheter stent materials
  • MRI Safe in all MR environments without conditions

Downloads

Please fill in the form below to request more information about Avalus

*Indicates Required Field

Your information will be processed and protected in accordance with our privacy statement

View our privacy statement

1

PERIGON Pivotal Trial data on file as of January 2021. The PERIGON Pivotal Trial regarding the Avalus valve is a prospective, interventional, nonrandomized, worldwide, multi-site trial, with each center following a common protocol. The study was designed in accordance with the recommendations of the EN ISO 5840:2009 standard for cardiac valve prostheses and the U.S. Food and Drug Administration (FDA) Heart Valve Guidance (2010; DRAFT) and conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. Valve-related events and deaths were adjudicated by an independent clinical events committee (CEC). All study echocardiograms were analyzed by an independent core laboratory (MedStar Health Research Institute, Washington, D.C.). Safety oversight was provided by an independent data and safety monitoring board (DSMB). This trial is registered at www.clinicaltrials.gov, NCT02088554.

2

The Avalus™ TVR data from the PERIGON study, compared to the TVR results of Magna Ease™ and Trifecta™ valves as presented in Colli A, Marchetto G,Salizzoni S, Rinaldi M, Di MarcoL, Pacini Det al. The TRIBECAstudy: (TRI)fecta (B)ioprosthesis (E)valuation versus (C)arpentier Magna-Easein (A)ortic position. Eur JCardiothorac Surg 2016;49:478–85

3

Colli A, Marchetto G,Salizzoni S, Rinaldi M, Di MarcoL, Pacini Det al. The TRIBECAstudy: (TRI)fecta (B)ioprosthesis (E)valuation versus (C)arpentier Magna-Easein (A)ortic position. Eur JCardiothorac Surg 2016;49:478–85

4

Ruzicka D.J. Hettich I, Hutter A, et al. The complete superannular concept. Circulation 2009; 120 (suppl 1):5139-5145.

*

No clinical data is available which evaluates the long-term impact of AOA treatment in patients.